CHF and CLBP are the main reasons I invested in Mesoblast - nothing disappoints me more than to see such a focus on GVHD while the two block buster treatments 'appear' to be sitting in the background with little progress ?
The CLBP trial needs to start this quarter as has continually been claimed by the company regardless of the FDA setback if the market is to have any confidence ?
As for the CHF FDA meeting ..... well this also needs to happen ? It has been more than 12 months since the FDA requested additional information on the CHF DREAM phase 3 trial and the meeting seems to have been postponed a few times - is this because the focus was on GVHD / Remestemcel-L .... who knows ?
Time for the company to deliver on multiple fronts
CEO Itescu needs to go, page-768
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |